Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML) [Yahoo! Finance]
Shattuck Labs, Inc. (STTK)
Company Research
Source: Yahoo! Finance
pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that the U.S. FDA has granted orphan drug designation (ODD) to lead clinical candidate SL-172154 for the treatment of AML. “AML patients have few options for treatment and a poor prognosis. FDA's decision to grant orphan drug designation to SL-172154 highlights the urgent need for new treatment options,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. “This is an important first step in our progression to later-stage clinical studies, and we look forward to presenting additional data from the Phase 1B dose expansion clinical trial of SL-172154 with azacitidine in frontline higher-risk myelodysplastic syndromes and TP53m AML patients during a poster presentation at the European Hematology Association 2024 Congress.” The FDA's Office of Orphan Products Development grants orphan status
Show less
Read more
Impact Snapshot
Event Time:
STTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STTK alerts
High impacting Shattuck Labs, Inc. news events
Weekly update
A roundup of the hottest topics
STTK
News
- Shattuck Labs, Inc. (NASDAQ: STTK) had its price target lowered by analysts at HC Wainwright from $28.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
- Hold For Now: Shattuck Labs' SL-172154 Potential In Early Trials [Seeking Alpha]Seeking Alpha
- Shattuck Labs, Inc. (NASDAQ: STTK) had its price target lowered by analysts at Citigroup Inc. from $10.00 to $9.00. They now have a "buy" rating on the stock.MarketBeat
- Shattuck Labs, Inc. (NASDAQ: STTK) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.MarketBeat
- Shattuck (STTK) Announces Positive Interim Data on Cancer Drug [Yahoo! Finance]Yahoo! Finance
STTK
Earnings
- 2/29/24 - Beat
STTK
Sec Filings
- 6/21/24 - Form 4
- 6/21/24 - Form 4
- 6/21/24 - Form 4
- STTK's page on the SEC website